Business of Optometry

Top Story

Omeros reports $12.6 million net loss in second quarter

August 31, 2016

Omeros reported a net loss of $12.6 million, or $0.32 per share, in the second quarter compared with a net loss of $16.7 million, or $0.44 per share, in the second quarter of 2015, according to a press release.

Revenues totaled $10 million, which were related to sales of Omidria (phenylephrine 1%/ketorolac 0.3%). Omidria revenues totaled $3.1 million a year ago.

EyeGate reports increased net loss in second quarter

August 30, 2016
EyeGate Pharmaceuticals reported a $3.823 million net loss for the second quarter of 2016, compared with a $1.541 million net loss in the second quarter of 2015. The…

Xiidra for dry eye now available in US

August 29, 2016
Shire announced that Xiidra, its twice-daily prescription eye drop that is FDA-approved for the treatment of dry eye disease, is now available by prescription in the…

FDA announces medical device user fee agreement

August 29, 2016
The FDA and the Advanced Medical Technology Association, the Medical Device Manufacturers Association and the Medical Imaging & Technology Alliance tentatively…

Xiidra for dry eye now available in US

August 29, 2016
Shire announced that Xiidra, its twice-daily prescription eye drop that is FDA-approved for the treatment of dry eye…
More »
Perspectives on Glaucoma

Home tonometer measured within 5 mm Hg of GAT in majority studied

August 26, 2016
The Icare Home device for self-tonometry use is reliable in obtaining measurements similar to those taken by Goldmann…
More »
Featured
Optometry's Meeting 2016

Optometry's Meeting 2016

Foundation Fighting Blindness launches retinal disease awareness campaign

August 29, 2016
The Foundation Fighting Blindness has recently launched the #HowEyeSeeIt campaign to raise awareness and research funds…
More »

Omeros reports $12.6 million net loss in second quarter

August 31, 2016
Omeros reported a net loss of $12.6 million, or $0.32 per share, in the second quarter compared with a net loss of $16.7 million, or $0.44 per share…

EyeGate reports increased net loss in second quarter

August 30, 2016
EyeGate Pharmaceuticals reported a $3.823 million net loss for the second quarter of 2016, compared with a $1.541 million net loss in the second…

Xiidra for dry eye now available in US

August 29, 2016
Shire announced that Xiidra, its twice-daily prescription eye drop that is FDA-approved for the treatment of dry eye disease, is now available by…

FDA announces medical device user fee agreement

August 29, 2016
The FDA and the Advanced Medical Technology Association, the Medical Device Manufacturers Association and the Medical Imaging & Technology…

Video

BLOG: Make the most of Google Adwords

August 25, 2016
“One of the biggest problems I see within Google Adwords is that optometrists advertise across a broad regional area,” says blogger…

NovaBay reports $2.7 million in net sales in second quarter

August 25, 2016
NovaBay Pharmaceuticals reported net sales of $2.7 million in the second quarter, a 164% increase from $1 million in the same period of 2015…

Inotek completes recruitment for phase 3 trial of trabodenoson

August 25, 2016
Inotek Pharmaceuticals completed active recruitment for MATrX-1, the first pivotal phase 3 trial of trabodenoson for the treatment of glaucoma…

Auven Therapeutics completes enrollment in phase 3 study of Seciera for dry eye

August 24, 2016
Auven Therapeutics completed enrollment in a phase 3 confirmatory study of Seciera for the treatment of dry eye disease, according to a press…

Zeiss reports revenue increase in first 9 months of fiscal year

August 24, 2016
Carl Zeiss Meditec reported a 6.7% increase in revenue in the first 9 months of its fiscal year, according to a press release. Revenue totaled…

From OSN Europe

Presbia completes purchase of Neoptics

August 23, 2016
Presbia Ireland Ltd., a wholly owned subsidiary of Presbia PLC, has purchased the assets of Neoptics AG. The purchase includes Neoptics’…

More Headlines »
morganatic-roan